Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: A prospective four arm observational study in Ethiopian patients

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Yimer, Getnet ^a,b   Gry, Marcus ^c   Amogne, Wondwossen ^a,b   Makonnen, Eyasu ^b   Habtewold, Abiy ^a,b   Petros, Zelalem ^b   Aderaye, Getachew ^b   Schuppe Koistinen, Ina ^d   Lindquist, Lars ^a   Aklillu, Eleni ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c ASTRAZENECA R AND D   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; COTRIMOXAZOLE; CREATININE; EFAVIRENZ; ETHAMBUTOL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; ISONIAZID; LAMIVUDINE; LIVER ENZYME; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; TENOFOVIR; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CHOLESTATIC HEPATITIS; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; ETHIOPIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER CELL DAMAGE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; THROMBOCYTE COUNT; TOXIC HEPATITIS; TREATMENT DURATION; TUBERCULOSIS; VIRUS LOAD; COMPLICATION; DRUG-INDUCED LIVER INJURY; HIV INFECTIONS; KAPLAN MEIER METHOD; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTITUBERCULAR AGENTS; DRUG-INDUCED LIVER INJURY; ETHIOPIA; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899424490     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094271     Document Type: Article

References (41)

1. Walker UA (2007) Antiretroviral therapy-induced liver alterations. Curr Opin HIV AIDS 2: 293-298.
2. Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD (2003) Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 34: 379-386. (Pubitemid 37444465)
3. Nunez M (2010) Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 52: 1143-1155.
4. Inductivo-Yu I, Bonacini M (2008) Highly active antiretroviral therapy-induced liver injury. Curr Drug Saf 3: 4-13. (Pubitemid 351227234)
5. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, et al. (2008) Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23: 192-202. (Pubitemid 351257678)
6. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, et al. (2006) An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174: 935-952. (Pubitemid 44564795)
7. Wares DF, Singh S, Acharya AK, Dangi R (2003) Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal. Int J Tuberc Lung Dis 7: 327-335. (Pubitemid 36433124)
8. Bica I, McGovern B, Dhar R, Stone D, McGowan K, et al. (2001) Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32: 492-497. (Pubitemid 32173638)
9. Jones M, Nunez M (2012) Liver toxicity of antiretroviral drugs. Semin Liver Dis 32: 167-176.
10. Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, et al. (2012) High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics J 12: 499-506.
11. Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, et al. (2011) Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients. PLoS One 6: e27810.
12. Mugusi S, Ngaimisi E, Janabi M, Minzi O, Bakari M, et al. (2012) Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania. PLoS One 7: e40180.
13. Elsharkawy AM, Schwab U, McCarron B, Burt AD, Daly AK, et al. (2013) Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser. J Clin Virol 58: 331-333.
14. Lamar ZS, Nunez M (2011) Higher Risk of Severe Drug-Induced Liver Injury among Hispanic HIV-Infected Patients after Initiation of Highly Active Antiretroviral Therapy. J Int Assoc Physicians AIDS Care (Chic) 10: 183-186.
15. Kalyesubula R, Kagimu M, Opio KC, Kiguba R, Semitala CF, et al. (2011) Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Afr Health Sci 11: 16-23.
16. Tostmann A, van den Boogaard J, Semvua H, Kisonga R, Kibiki GS, et al. (2010) Antituberculosis drug-induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients. Trop Med Int Health 15: 268-272.
17. Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, et al. (2010) Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 105: 2396-2404.
18. Stine JG, Lewis JH (2011) Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol 7: 875-890.
19. Karvellas CJ, Safinia N, Auzinger G, Heaton N, Muiesan P, et al. (2010) Medical and psychiatric outcomes for patients transplanted for acetaminophen-induced acute liver failure: a case-control study. Liver Int 30: 826-833.
20. Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemba L, et al. (2007) Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 21: 1301-1308. (Pubitemid 46883484)
21. Tostmann A, Boeree MJ, Harries AD, Sauvageot D, Banda HT, et al. (2007) Short communication: antituberculosis drug-induced hepatotoxicity is unexpectedly low in HIV-infected pulmonary tuberculosis patients in Malawi. Trop Med Int Health 12: 852-855. (Pubitemid 46998292)
22. Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, et al. (2008) Antituberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. PLoS ONE 3: e1809.
23. Mugusi SF, Ngaimisi E, Janabi MY, Mugusi FM, Minzi OM, et al. (2012) Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania. Antivir Ther 17: 265-274.
24. Daly AK (2010) Drug-induced liver injury: past, present and future. Pharmacogenomics 11: 607-611.
25. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, et al. (2009) HLAB*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41: 816-819.
26. Russmann S, Jetter A, Kullak-Ublick GA (2010) Pharmacogenetics of drug-induced liver injury. Hepatology 52: 748-761.
27. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, et al. (2011) Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 89: 806-815.
28. World Health Organization, HIV/AIDS programme. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2006 revision. Available from http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf?ua=1 Section accessed [5 February 2014]
29. M'Kada H, Munteanu M, Perazzo H, Ngo Y, Ramanujam N, et al. (2011) What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI). Regul Toxicol Pharmacol 60: 290-295.
30. AIDS Clinical Trials Group, Table of Grading Severity of Adult Adverse Experiences, Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, Md, USA. 1996.
31. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD (2000) Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283: 74-80. (Pubitemid 30038386)
32. Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, et al. (2003) An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS 17: F7-10.
33. McRae MP, Lowe CM, Tian X, Bourdet DL, Ho RH, et al. (2006) Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther 318: 1068-1075. (Pubitemid 44268312)
34. Lee LS, Pham P, Flexner C (2012) Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz. Ann Acad Med Singapore 41: 559-562.
35. Neukam K, Mira JA, Ruiz-Morales J, Rivero A, Collado A, et al. (2011) Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. J Antimicrob Chemother 66: 2605-2614.
36. Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, et al. (2010) Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 88: 676-684.
37. Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel KD, et al. (2011) Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. The Journal of antimicrobial chemotherapy 66: 2350-2361.
38. Mukonzo JK, Okwera A, Nakasujja N, Luzze H, Sebuwufu D, et al. (2013) Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis 13: 261.
39. Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, et al. (2011) Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis. Clin Pharmacol Ther 90: 406-413.
40. Sterling TR, Pham PA, Chaisson RE (2010) HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis 50 Suppl 3: S223-230.
41. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, et al. (1999) Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 180: 607-613. (Pubitemid 29411344) Partnership Partnership